Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibiotic-induced Malassezia expansion in the infant gut promotes early-life immune dysregulation and airway inflammation in mice.

Nature communications·2026

Same author

Early-life gut fungi as modulators of metabolic development.

Trends in endocrinology and metabolism: TEM·2026

Same author

Impact of maternal, infant, and household factors on early-life gut microbiome development in a rural setting.

The ISME journal·2026

Same author

Echocardiographic predictors of adverse outcomes in infants with congenital diaphragmatic hernia.

Journal of perinatology : official journal of the California Perinatal Association·2026

Same author

Neurodevelopmental Outcome after Late-Onset Bacterial Sepsis in Infants Born before 29 Weeks' Gestation.

American journal of perinatology·2026

Same author

Investigating the Effects of Pharmacist Involvement on Emergency Department Outcomes: A Retrospective Cohort Study.

The Canadian journal of hospital pharmacy·2026

Search research articles

Related Experiment Video

Updated: Sep 29, 2025

Probiotic Studies in Neonatal Mice Using Gavage

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Multi-strain probiotics for extremely preterm infants: a randomized controlled trial.

Belal Alshaikh^1,2, Jumana Samara^3,4,5, Shirin Moossavi^3,4

¹Neonatal Nutrition and Gastroenterology Program, University of Calgary, Calgary, AB, Canada. balshaik@ucalgary.ca.

Pediatric Research

|March 22, 2022

Summary

Probiotics significantly reduced the time to full enteral feeds in extremely low-birth-weight infants. These beneficial bacteria also improved tolerance to cow

More Related Videos

Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings

Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings

Published on: February 7, 2025

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

Related Experiment Videos

Last Updated: Sep 29, 2025

Probiotic Studies in Neonatal Mice Using Gavage

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings

Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings

Published on: February 7, 2025

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

Area of Science:

Neonatal Medicine
Microbiome Research
Gastroenterology

Background:

The impact of probiotics on the intestinal microbiota and feeding tolerance in extremely low-birth-weight (ELBW) infants is not well understood.
Establishing optimal feeding practices and gut health is critical for the survival and development of ELBW infants.

Purpose of the Study:

To investigate the effects of probiotics on intestinal microbiota composition in ELBW infants.
To assess the impact of probiotics on feeding tolerance and clinical outcomes in ELBW infants.

Main Methods:

A randomized controlled trial involving ELBW infants assigned to receive probiotics or no intervention.
Stool sample analysis to evaluate changes in intestinal microbiota.
Monitoring of feeding progression, incidence of hematochezia, and need for specialized formulas.

Main Results:

Infants receiving probiotics achieved full enteral feeds significantly sooner (MD -1.8 days).
Probiotic use was associated with a trend towards lower incidence of hematochezia and reduced need for extensively hydrolyzed or amino acid-based formulas.
Multi-strain probiotics increased fecal Bifidobacterium and Lactobacillus while reducing Candida abundance.

Conclusions:

Probiotics can sustain beneficial intestinal bacteria like Bifidobacterium and Lactobacillus in extremely preterm infants.
Probiotic supplementation may improve feeding tolerance and reduce the time to achieve full enteral feeds in ELBW infants.
Probiotics show potential in improving tolerance to cow's milk protein supplements in this vulnerable population.